Login to Your Account

Partnership Breakup Nets $30M For NPS, mGluR For AstraZeneca

By Donna Young

Wednesday, October 10, 2007
NPS Pharmaceuticals Inc. and AstraZeneca plc mutually agreed to end their six-year partnership to discover and develop drugs targeting metabotropic glutamate receptors (mGluRs). (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription